Novavax to Present at the 13th Annual Needham Healthcare Conference
April 02 2014 - 4:10PM
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company,
announced today that Stanley C. Erck, President and Chief Executive
Officer, will present at the 13th Annual Needham Healthcare
Conference on April 9, 2014 at 12:10 pm ET in New York City at the
Westin Grand Central Hotel.
A live webcast link for the presentation will be available via
the company website at www.novavax.com under Investor
Info/Events.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biopharmaceutical company creating novel vaccines and vaccine
adjuvants to address a broad range of infectious diseases
worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine
candidates to efficiently and effectively respond to both known and
newly emergent diseases. Novavax is involved in several
international partnerships, including collaborations with Cadila
Pharmaceuticals of India, LG Life Sciences of Korea and PATH, and
recently acquired Isconova AB, a leading vaccine adjuvant company
located in Sweden. Together, Novavax' network supports its global
commercialization strategy to create real and lasting change in the
biopharmaceutical and vaccinology fields. Additional information
about Novavax is available on the company's website,
novavax.com.
Forward-Looking Statements
Statements herein relating to the future of Novavax and the
ongoing development of its vaccine and adjuvant products are
forward-looking statements. Novavax cautions that these forward
looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include those identified under the heading "Risk
Factors" in the Novavax Annual Report on Form 10-K for the year
ended December 31, 2013, filed with the Securities and Exchange
Commission (SEC). Investors are cautioned not to place considerable
reliance on the forward-looking statements contained in this press
release. You are encouraged to read company filings with the SEC,
available at sec.gov, for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this document, and the company
undertakes no obligation to update or revise any of the statements.
The company's business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From May 2023 to May 2024